Corticosteroid-Responsive Dermatoses Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Corticosteroid-Responsive Dermatoses Market
Corticosteroid-Responsive Dermatoses Market: By Type (Glucocorticoids and Mineralocorticoids), By Disorder (Rheumatoid Neutrophilic Dermatoses, Acute febrile Neutrophilic Dermatoses, Others) & By Region-Forecast (2016-2021)
Report Code : HCR 0224
Published On: 27 January, 2016   Updated On: 27 January, 2016

  • Report Description
  • Table of Contents
  • Customization Options
Dermatosis is a condition wherein the skin dermis, hair, nail, etc has an irritation or an anomaly. Corticosteroids are usually used to treat inflammation, but it is observed that corticosteroids sometimes also helped alleviate dermatoses. Corticosteroids, besides their inflammation control action are useful in treating disorders that are caused by hyperactivity of the immune response. Corticosteroids’ has side effects, such as allergic responses. Corticosteroids are to be used as a topical ointment only in skin regions with inflammation. Globally, development of new technology, rise in the demand for corticosteroid-responsive dermatoses, and increasing government initiative are the prime growth drivers of global corticosteroid-responsive dermatoses market. In addition, increase in adoption of corticosteroid-responsive dermatoses, and emerging economies such as China, India and others, will create new opportunities for global corticosteroid-responsive dermatoses market. However, higher cost of research and development, and harmful side effects are the key restraints for global corticosteroid-responsive dermatoses market.

This report identifies the global corticosteroid-responsive dermatoses market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global corticosteroid-responsive dermatoses market.
 
Corticosteroid-Responsive Dermatoses Market

Geographically North America dominated global corticosteroid-responsive dermatoses market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, and modernizing healthcare infrastructure in this region. Among all the types, mineralocorticoids has the highest market share in global corticosteroid-responsive dermatoses market.

This report segments global corticosteroid-responsive dermatoses market on the basis of disorder, type, and regional market as follows:
  • Corticosteroid-Responsive Dermatoses Market, By Disorder: Rheumatoid Neutrophilic Dermatoses, Acute febrile Neutrophilic Dermatoses, Dermatoses Papulosa Nigra, Dermatoses Neglecta, Dermatoses Cinecienta, Linear Lichenoid Dermatoses, Digitate Dermatoses, Contagious Pustular Dermatoses, Transient Acantholytic Dermatoses, and Juvenile plantar Dermatoses
  • Corticosteroid-Responsive Dermatoses Market, By Type: Glucocorticoids, and Mineralocorticoids
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the corticosteroid-responsive dermatoses market. Some of the major companies’ profiles in detail are as follows:
  • Novartis International AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Medcis
  • Nycomed US Inc
1. Corticosteroid-Responsive Dermatoses Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Corticosteroid-Responsive Dermatoses Market– Market Forces
   4.1. Drivers
      4.1.1. Development of new technology
      4.1.2. Rise in the demand for corticosteroid-responsive dermatoses
      4.1.3. Increasing government initiative
   4.2. Restraints
      4.2.1. Higher cost of research and development
      4.2.2. Harmful side effects
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of corticosteroid-responsive dermatoses
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Corticosteroid-Responsive Dermatoses Market, By Disorder
   5.1. Rheumatoid Neutrophilic Dermatoses
   5.2. Acute febrile Neutrophilic Dermatoses
   5.3. Dermatoses Papulosa Nigra
   5.4. Dermatoses Neglecta
   5.5. Dermatoses Cinecienta
   5.6. Linear Lichenoid Dermatoses
   5.7. Digitate Dermatoses
   5.8. Contagious Pustular Dermatoses
   5.9. Transient Acantholytic Dermatoses
   5.10. Juvenile plantar Dermatoses
6. Corticosteroid-Responsive Dermatoses Market, By Type
   6.1. Glucocorticoids
   6.2. Mineralocorticoids
7. Corticosteroid-Responsive Dermatoses Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Corticosteroid-Responsive Dermatoses – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   9.1. Novartis International AG
   9.2. GlaxoSmithKline plc
   9.3. Pfizer Inc.
   9.4. Medcis
   9.5. Nycomed US Inc
   9.6. Merck
   9.7. Nova Biomedical Corporation
   9.8. Pharmaco-Kinesis Corporation
   9.9. Incyte Corporation
   9.10. Bayer AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll